ABSTRACT
Introduction Exposure to commercial marketing of cannabis vape products (CVPs) may encourage CVP use, yet little is known about how these products are marketed. This study examined marketing descriptions of CVPs’ functions and benefits in an online retail environment.
Methods Product descriptions from a sample of 343 CVPs from 78 top-selling cannabis brands in 2023 were obtained from a large cannabis e-commerce website. Each description was thematically coded based on the promoted product features.
Results The most frequently mentioned product feature was flavor profile and sensation (74.1%), including general and specific flavor descriptors (e.g., fruit flavors) and sensory experiences (e.g., sweet, spicy). Psychoactive effects were noted in 47.5% of the descriptions, detailing potency or effects such as feeling “high,” “stoned,” or “buzzed.” Product quality, such as “purity,” “natural,” or “organic,” was mentioned in 42.3% of the descriptions. Other product benefits described included mood enhancement (33.8%), reduced harm (24.2%), relaxation/tension reduction (23.9%), therapeutic effects (18.4%), focus/creativity (16.6%), convenience/discreetness (11.1%), socialization enhancement (6.7%), and physical performance enhancement (6.1%).
Discussion Some frequently promoted product features of CVPs, such as flavor and sensation and psychoactive effects, may particularly appeal to younger consumers for non-medical use. Meanwhile, attributes surrounding high product quality and reduced harm may reduce individuals’ perceived risks of CVP use and may violate state restrictions on therapeutic claims. Additional research assessing the influence of exposure to marketed product features on product perceptions and use behaviors among priority populations is needed to inform regulations and enforcement.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
